CMC And GMP Updates In Brief: Continuous Manufacturing, Accelerated CMC Reviews
Executive Summary
ICH general assembly adopts guidelines on continuous manufacturing and risk management; US FDA opens pilot project to expedite CMC reviews for products with accelerated review timelines; other recent topics include quality maturity inspections and compounding standards.
You may also be interested in...
Gene Therapy Manufacturing: US FDA Wants Academics Brought ‘Into The Loop’
FDA’s Peter Marks says educating academics about CMC would help them understand why it is necessary to do things in a standardized way. He predicts the field will move away from individual manufacturing platforms in the next five to 10 years.
US FDA Ready To Move Forward On Developing Quality Management Maturity Rating System
The US FDA will begin work on operationalizing a Quality Management Maturity rating system following a public vote of confidence from its outside advisory committee. There are plenty of key details still to be worked out.
Drug GMP and CMC Updates In Brief: Guidance Advances on Several Fronts
The US FDA revised two drug good manufacturing practice inspection programs in its compliance manual to reflect certain ICH guidance documents, efforts to control nitrosamine impurities and the use of inspection alternatives for evaluating facilities. Plus more recent developments in GMP and CMC compliance.